Once-daily Highly Active Antiretroviral Therapy (HAART). Present or failure?;Tratamiento antirretroviral de gran actividad administrado una vez al día: ¿Presente o futuro?

Medicina Clinica

Volumn 121, Issue 8, 2003, Pages 304-309

  Pulido, Federico ^a   Hernando, Asunción ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

Adherence; Antiretroviral therapy; Once daily therapy

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG UTILIZATION; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; PATIENT CARE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT;

EID: 0141504948     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050722     Document Type: Review

References (38)

1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
3. Puigventós F, Riera M, Delibes C, Peñaranda M, De la Fuente L, Boronat A. Estudios de adherencia a los fármacos antirretrovirales. Una revisión sistemática. Med Clin (Barc) 2002;119:130-7.
4. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biological outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.
5. Grupo de estudio Vivir +. Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España. Med Clin (Barc) 2002;119:721-4.
6. Bartlett A DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-77.
7. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavirlamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86.
8. Knobel H, Rubio R, Miró JM, Gatell JM, Del Campo A. Adherence to antiretroviral therapy: the patient's perspective [abstract 8571. Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999; Lisboa.
9. Moyle G. The APPT-1 study: assessing patients' preferred treatments [abstract P99]. Abstracts of the 6th International Congress on Drug Therapy in HIV-Infection; 2002, noviembre 17-22; Glasgow.
10. Bass D, Smith MF. HIV patients prefers once-daily regimens [abstract MoPeB3290]. Abstracts of the 14th, International AIDS Conference; 2002, julio 7-12; Barcelona.
11. Jordan J, Carranza-Rosenzweig J, Pathak D, Pilon T. Perceived influence of regimen characteristics on adherence [abstract P121]. Abstracts of the 4th International Congress on Drug Therapy in HIV Infection; 2000, octubre 22-26; Glasgow.
12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23: 1296-310.
13. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Adddis A, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-16.
14. Katlama C, Rachlis A, Staszewski S, Becker S, Maa JF, Bessen LJ, et al. Better virologic suppression after substitution of protease inhibitors with efavirenz in patients with undetectable viral loads [abstract 06]. Abstracts of the 8th European Conference on Clinic Aspects and Treatment of HIV-Infection; 2001, octubre 28-31; Atenas.
15. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antirretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002;51(RR-7):1-55.
16. Kearney B, Damle B, Plummer A, Sayre J, Zhang X, Ryan K, et al. Tenofovir DF and didanosine EC: investigation of pharmacokinetic (PK) drug-drug and drug-food interactions [abstract P186]. Abstracts of the 6th International Congress on Drug Therapy in HIV-Infection 2002; noviembre 17-22, Glasgow.
17. Kearney BP, Isaacson E, Sayre J, Namini H, Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanisine dose reduction [abstract 533]. Abstracts of the 10th Conference on Retroviruses and Opportinistic Infections; 2003, febrero 9-14; Boston.
18. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001;6: 249-53.
19. Maggiolo F, Arici C, Gregis G, Quinzan G, Ripamonti D, Ravasio L, et al. A controlled, randomized, prospective study on a once-a-day therapy for HIV infection [abstract H-163]. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002, septiembre 27-30, San Diego.
20. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1-infected adults in Senegal. AIDS 2003;17:1017-22.
21. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Serem D, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602.
22. Molina JM, Ferchal F, Journot V, Maillard A, Noe E, Raffi F, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in treatment naive HIV-infected adults: 96-week follow-up of the ANRS 091 trial [abstract P221]. Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001, octubre, 28-31; Atenas.
23. Molina JM, Ferchal F, Rancinan C, Yeni P, Rozembaum W, Journot V, et al. Once-daily combination of entricitabine, didanosine and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48 week results of a prospective randomised multicenter trial (ALIZE-ANRS 99) [abstract 551]. Abstracts of the 10th Conference on Retroviruses and Opportinistic Infections; 2003, febrero 9-14; Boston.
24. Staszeswski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Med 2000;1:162-3.
25. Van Leth F, Hassink E, Phaunkhak P, Miller S, Gazzard B, Cahn P, et al. Results of the 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [abstract: 176]. Abstracts of the 10th Conference on Retroviruses and Opportinistic Infections; 2003, febrero 9-14; Boston.
26. Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr 2001;27:260-5.
27. López-Cortés LF, Ruiz-Valderas R, Viciana P, Mata R, Gómez-Vera J, Alarcón A, et al. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. J Acquir Immune Defic Syndr 2003;32:240-2.
28. Montaner JSG, Saag MS, Barylski C , Siemon-Hryczyk P. FOCUS study: saquinavir qd regimen versus efavirenz qd regimen 24 week analysis in HIV infected patients [abstract I-670]. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001, diciembre 16-19; Chicago.
29. Eron JJ, Bernstein B, King M, Manning L, Bertz R, Beall G, et al. Once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up [abstract 409-W]. Abstracts of the 9th Conference on Retroviruses and Opportinistic Infections; 2002, febrero, 24-28.
30. Arribas JR, Pulido F, Miró JM, Costa MA, González J, Rubio R, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1 infected patients with fewer than 100 CD4 cell and opportunistic diseases: the EFAVIP Study (Efavirenz in Very Inmunosuppressed Patients). AIDS 2002;16:1554-6.
31. Pulido F, Arribas JR. Treatment of advanced HIV infection. J Antimicrob Chemother 2003;51:225-7.
32. Ena J, Pascuau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003;36:1186-90.
33. Staszewski S, Gallant J, Pozniak AL, Suleiman JMAH, DeJesus E, Koening E, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results [abstract LBO 171. Abstracts of the 14th International AIDS Conference; 2002, julio, 7-12; Barcelona.
34. Cohen C, Lang J, Luskin-Hawk R, Pegram S, Elton R, Green S, et al, Efavirenz in combination with stavudine and didanosine or lamivudine is well tolerated and eficacious [abstract 128]. Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 1999, octubre, 23-27; Lisboa.
35. Pollard R, Ive P, Farthing C, Whelden M, Thompson S, Brett-Smith H. Stavudine XR vs stavudine IR as part of potent antiretroviral combination therapy: 24-week safety and antiviral efficacy [abstract 411-W]. Abstracts of the 9th Conference on Retroviruses and Opportinistic Infections; 2002, febrero 13-28.
36. Sension MG, Bellos NC, Johnson J, Sepulveda GE, DeJesús E, Santana JL, et al. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and protease inhibitor in suppresed patients. HIV Clin Trials 2002;3:361-70.
37. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clavel F. Kinetics of antiviral activity and intracellular pharmacokinetics of human immuno-deficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 1999;43:2629-34.
38. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, et al. Short cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-6.